We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are excellent examples along ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Crohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...

MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

(American Journal of Gastroenterology) Results of the phase III GRAVITI study support the use of subcutaneous guselkumab (Tremfya) for moderately to severely active Crohn's disease ...

The findings were seen to set the stage for a significant new entrant in the psoriasis treatment landscape, which is led by injectable treatments such as AbbVie’s (NYSE: ABBV) Skyrizi (risankizumab) ...